News Agency
The Times

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

  • Written by PR Newswire

HONG KONG, Aug. 18, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. The Phase III trial will evaluate the clinical efficacy and assess the safety...

Read more: Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for...

Selecting Steel Plate for Industrial and Fabrication Projects

Start with the job requirements A successful fabrication project starts with material that suits the work it must perform. Choosing steel plate involves more than selecting a thickness from a stock list. Designers and procurement teams need to consider the load... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion